FDA Classifies Fibromyalgia Nerve Stimulator as Class II
Published Date: 5/29/2026
Rule
Summary
The FDA is officially classifying the transcutaneous electrical nerve stimulator for fibromyalgia as a Class II device, meaning it’s safe and effective with some special rules. This change helps patients get easier access to this innovative treatment by cutting down red tape. The new classification is effective May 29, 2026, and could speed up device availability without extra costs for makers or users.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
Device moved to Class II (easier access)
The FDA officially classified the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a Class II (special controls) device effective May 29, 2026 (classification applicable May 18, 2022). FDA says this classification reduces regulatory burdens and can enhance patients' access to this treatment and could speed up device availability without extra costs for makers or users.
De Novo device can serve as 510(k) predicate
Because the device was classified via the De Novo process, it can serve as a predicate device for future devices, letting other sponsors use the less-burdensome 510(k) process instead of a De Novo request or premarket approval application.
Device is subject to 510(k) submission now
The document states that transcutaneous electrical nerve stimulators to treat fibromyalgia symptoms are subject to premarket notification under section 510(k) of the FD&C Act at this time (FDA has not determined the device type should be exempt under section 510(m)).
Special controls require safety testing and labeling
FDA established special controls that require non-clinical performance testing (electrical parameter characterization, electrode performance, impedance monitoring), biocompatibility for patient-contacting components, electrical/thermal/mechanical safety and electromagnetic compatibility testing, software verification/validation/hazard analysis, and specific labeling (treatment regimes, electrode shelf life/reuse, device technical summaries, and user instructions).
Device is prescription-only
FDA identifies the transcutaneous electrical nerve stimulator to treat fibromyalgia symptoms as a prescription device, meaning patients must receive it through a prescription rather than over-the-counter.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-10621, Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Suturing Device for Altering Gastric Anatomy for Weight Loss
The FDA is officially classifying the endoscopic suturing device for weight loss as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative tool faster and ensures it’s safe and effective. The new rules took effect on May 28, 2026, and could save time and money for makers and users alike.
Next: 2026-10709, Bacillus Thuringiensis Cry1B.34.1, Bacillus Thuringiensis Cry1B.61.1 and Adiantum Trapeziforme var. Braziliense IPD083Cb Proteins; Pesticide Tolerances
The EPA just said it’s okay to have tiny amounts of three special proteins—Cry1B.34.1, Cry1B.61, and IPD083Cb—in all food and animal feed without setting strict limits. This helps farmers and food makers use these proteins safely in crops to protect plants from pests. The new rule kicks in on May 29, 2026, and anyone who wants to object has until July 28, 2026, to speak up.